Biocon receives CDSCO approval for its Liraglutide drug in India
Biocon Limited, a global biopharmaceutical company, has announced that it has received regulatory approval in India for its Liraglutide drug substance. Its wholly owned subsidiary, Biocon Pharma Limited, has also secured approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge) from the Central Drugs Standard Control Organisation (CDSCO).
The product is a generic version of Victoza®, used as an adjunct to diet and exercise to improve glycemic control in adults, adolescents, and children aged 10 years and older with Type 2 Diabetes Mellitus that is not adequately managed.
Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, commented, 'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon's mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India''
This approval was granted under the CDSCO's recently introduced 101 route. This regulatory pathway allows for the recognition of approvals issued by referenced and established foreign regulatory agencies, thereby facilitating faster access to critical medicines in India.
Glucagon-like peptide-1 (GLP-1) therapies, including Liraglutide, are being recognized as a growing segment in diabetes management. Biocon has stated its intent to expand its portfolio in this category as part of its future business strategy.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
12 minutes ago
- Business Upturn
Epigral acquires 26% stake in renewable energy SPV for Rs 21.38 crore
By Aman Shukla Published on June 4, 2025, 11:13 IST Epigral Limited has announced the execution of agreements to invest in a renewable energy project in Gujarat. On June 4, 2025, the company entered into a Share Subscription and Shareholder's Agreement with Prozeal Green Power Private Limited and Pro-Zeal Green Power Ten Private Limited. Additionally, it signed an Energy Supply Agreement with Pro-Zeal Green Power Ten Private Limited to source 19.80 MW of Wind Solar Hybrid (WSH) power as a captive consumer. As part of this transaction, Epigral will subscribe to at least 26% of the securities—comprising equity and optionally convertible debentures—of Pro-Zeal Green Power Ten Private Limited, a special purpose vehicle (SPV) formed to develop and operate the WSH power project. The investment will be made in one or more tranches, totaling approximately ₹21.38 crore, and will be through cash consideration. The SPV was incorporated on January 2, 2025, and is yet to begin commercial operations. Its current paid-up capital is ₹1 lakh. Following the transaction, Pro-Zeal Green Power Ten will become an associate of Epigral. The ownership in the SPV will be held in the ratio of 26:74 by Epigral and Prozeal Green Power Private Limited, respectively. This strategic move aligns with Epigral's efforts to secure power for its future expansion projects while progressing towards its sustainability goals. The transaction has been carried out at arm's length and does not require any regulatory approvals. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
12 minutes ago
- Business Upturn
Chennai Petroleum to re-enter fuel retail market with Rs 400 crore investment
By Aman Shukla Published on June 4, 2025, 11:28 IST Chennai Petroleum Corporation Limited (CPCL) has announced plans to set up retail fuel outlets for the sale of petrol and diesel, marking its return to the fuel retail segment after nearly 20 years. The initiative has received approval from the Ministry of Petroleum and Natural Gas. CPCL has allocated approximately ₹400 crore as capital expenditure for this project over the next two to three years. The first phase of fuel retail outlets is expected to be launched during the company's Diamond Jubilee year. Site selection for these outlets is currently underway, with decisions based on market potential and strategic location analysis. CPCL is taking a phased and cautious approach, with plans to expand into additional states depending on market response and operational conditions. The move is part of CPCL's strategy to diversify its business operations and strengthen its position in the downstream petroleum sector. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
12 minutes ago
- Business Upturn
SPARC shares drop nearly 20% after key drug trial fails
By Aman Shukla Published on June 4, 2025, 11:35 IST Shares of Sun Pharma Advanced Research Company (SPARC) declined sharply by nearly 20% after the company announced the discontinuation of clinical trials for its experimental drug Vibozilimod (SCD-044). The drop came following an update from Sun Pharmaceutical Industries Limited, SPARC's collaborator, which revealed that the Phase 2 trials for Vibozilimod failed to meet their primary efficacy endpoints. The drug, which was being tested for treating moderate-to-severe psoriasis and atopic dermatitis, did not show the required 75% improvement in PASI and EASI scores by Week 16. As a result, no further trials will be conducted, marking a significant setback for both companies' specialty drug pipelines. Shares of Sun Pharma Advanced Research Company (SPARC) opened at ₹185.00 and touched an intraday low of ₹156.14, reflecting a sharp decline. The stock did not move above its opening price, indicating bearish sentiment. SPARC is currently trading closer to its 52-week low of ₹109.30, far below the 52-week high of ₹258.00. As of 11:34 AM, the shares were trading 17.95% lower at Rs 160.15. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
